ARS Pharmaceuticals (SPRY) Operating Margin (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Operating Margin data on file, last reported at 265.18% in Q1 2026.

• For the quarter ending Q1 2026, Operating Margin rose 20111.0% year-over-year to 265.18%; the trailing twelve-month figure through Mar 2026 stood at 204.49% (down 17662.0% YoY), and the FY2025 full-year result was 212.92%, down 20947.0% from the prior year.
• Operating Margin retreated to 265.18% in Q1 2026, from 147.63% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 54.51% in Q4 2024 to a low of 206030.0% in Q2 2023.
• A 5-year average of 23919.37% and a median of 1051.64% in 2024 frame the typical range for Operating Margin.
• Across the five-year window, Operating Margin slumped 20466276 bps in 2023 and soared 20296200 bps in 2024, its largest moves.
• Tracing SPRY's Operating Margin over 5 years: stood at 3507.94% in 2022, then tumbled by 5773 bps to 206030.0% in 2023, then soared by 100 bps to 54.51% in 2024, then tumbled by 371 bps to 147.63% in 2025, then tumbled by 80 bps to 265.18% in 2026.
• Business Quant data shows SPRY's Operating Margin at 265.18% in Q1 2026, 147.63% in Q4 2025, and 163.66% in Q3 2025.